Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on current treatment landscape of patients with ovarian cancer from Clinical Care Options (CCO)

Bradley J. Monk, MD, FACS, FACOG Released: December 3, 2020